Navigation Links
Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Date:10/20/2010

SEATTLE, Oct. 20 /PRNewswire/ -- Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ™ profiling service and immunoSEQ Analyzer™ bioinformatics software platform.  Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

"ImmunoSEQ represents one of the first specific applications of next-generation sequencing technology," offers Chad Robins, CEO and Founder of Adaptive TCR. "We have delivered the Hubble Telescope as compared to a pair of binoculars to look at the adaptive immune system."

ImmunoSEQ assays use proprietary chemistry to amplify the rearranged CDR3 regions of T-cell receptor (TCR) genes responsible for most TCR diversity.  Each immunoSEQ assay can generate millions of cell-specific sequences, allowing a remarkably deep characterization of the T-cell repertoire in any sample.  To analyze this large amount of data, Adaptive TCR provides access to the immunoSEQ Analyzer, a bioinformatics software platform comprising a suite of tools designed specifically to handle immunoSEQ data.  

"Using DNA sequencing to look at cells of the immune system is particularly powerful," said Dr. Harlan Robins, a computational biologist at the Fred Hutchinson Cancer Research Center and co- founder of Adaptive TCR. "By bringing together unique amplification chemistries, massively parallel sequencing and powerful, user-friendly software, we are providing access to the adaptive immune system in unbelievable detail."  

In addition to providing information on the basic functioning of the immune system, immunoSEQ data can contribute to the understanding and development of many important medical conditions and applications, including cancer immunotherapy, autoimmune disorders, vaccine development, and infectious disease.  "We know that T cells are involved in autoimmune diseases like Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis and others," noted Dr. Christopher Carlson, an investigator at the Fred Hutchinson Cancer Research Center and a co-founder of Adaptive TCR.  "Now we can examine what's going on in incredible detail, and hopefully we will find tests based on T-cell repertoires that give physicians prognostic information and treatment guidance."

ImmunoSEQ assays and the immunoSEQ Analyzer are easily available to any researcher.  The researcher or clinician need only provide a DNA sample; the company does all the laboratory work, and uploads the resulting sequence data to a secure web site that is available to the researcher at all times. "The true value to our clients lies in the combination of the assay with a user-friendly, powerful software suite for data analysis, visualization, and interpretation," adds CEO Robins.  

Robins believes that the industry is at the very beginning, "as our technology becomes increasingly powerful, we look forward to witnessing clients using immunoSEQ to answer fundamental questions in the field of adaptive immunity, leading to a better quality of life for people afflicted with dysfunctional immune systems."

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR's proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.


'/>"/>
SOURCE Adaptive TCR Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
2. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
5. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
6. CoreLab Partners Launches New DXA Imaging Service Offerings
7. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
8. InSightec Launches ExAblate(R) One and ExAblate(R) OR Systems at CIRSE 2010
9. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
10. HelixLife Launches Custom Health Supplements, Anti-Aging and Acne Skin Serums
11. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
(Date:1/19/2017)... , Jan. 18, 2017 The global ... USD 92.9 billion by 2025, according to a ... industry has been adaptive of the function of ... as 2002. Among the services outsourced, clinical trial ... instance, Johnson & Johnson was the first pharmaceutical ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):